CSRC approved the IPO registration of Dashuwei on the ChiNext Board.
On January 23rd, the China Securities Regulatory Commission issued the "Approval for the Initial Public Offering of Shares of Shenzhen MegaChip Electronics Co., Ltd."
On January 23rd, the China Securities Regulatory Commission issued the approval for the initial public offering of shares by Shenzhen Da Puwei Electronics Co., Ltd. It is reported that Da Puwei plans to go public on the Shenzhen Stock Exchange's Growth Enterprise Market, with Guotai Haitong as the sponsor institution, intending to raise 1.87785 billion yuan.
According to the prospectus, Da Puwei is mainly engaged in the research and sales of data center enterprise SSD products. It is a leading company in the industry, with few domestic companies possessing the full stack self-developed capabilities of enterprise SSD "controller chip + firmware algorithm + module" and achieving mass shipments of semiconductor storage products.
Da Puwei focuses on data center enterprise SSDs, with products covering generations from PCIe 3.0 to 5.0, fully meeting the product needs of various types of customers. During the reporting period, the company's cumulative shipments of enterprise SSDs exceeded 4,900PB, with over 75% of shipments featuring self-developed controller chips. According to IDC data, the company's market share in the domestic enterprise SSD market has remained at the forefront in the past three years, with international vendors still dominating the market.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


